SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " BIO " 2,874 found 🔀 AI-powered Shuffle
'They showed their commitment to the club'
West Bromwich Albion manager James Morrison is delighted with his side's defensive work after playing for nearly an hour with 10 men in the win at Derby.
Biology Professor Earns Prestigious Fulbright Appointment
College of Charleston professor, Andrew Shedlock, will deliver high-impact STEM and AI education to faculty and students in Vietnam through the prestigious Fulbright Specialist Program.
UT San Antonio prepares biomedical researchers for entrepreneurial innovation
UT San Antonio is preparing biomedical researchers to think beyond scientific discovery, equipping them to consider how promising research can move from the laboratory toward real-world impact.
Two Tiny Lifeforms Built a Bridge Too Small to See—and May Have Made Humanity Possible
Stromatolites, formed by microbial mats, hold evidence of a symbiotic relationship that possibly kickstarted complex life billions of years ago.
USC Dornsife professor Moh El-Naggar named director at Carnegie
Biophysicist and microbiologist will lead Carnegie’s Biosphere Sciences and Engineering, maintains appointment and research at USC Dornsife
Stores collecting biometric data in Monroe County must tell customers
Monroe County mandates businesses to post notices when using biometric identification technology, enhancing transparency and protecting consumers.
How 'parachute science' is failing the world's tropical insects
Monash University scientists have developed a global framework to tackle a major blind spot in biodiversity conservation: Insects underpin ecosystems and food production but remain largely invisible to ...
Rubio visits Ecuador as Trump-friendly leader helps the US counterdrug push in the region
U.S. Secretary of State Marco Rubio visits Ecuador on the second leg of a three-nation tour of South America aimed at boosting security cooperation with conservative leaders.
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
Upcoming opportunities
🔬 Know a scientist whose sustained service to ASBMB and professional accomplishments have advanced the molecular biosciences? Consider nominating them as an ASBMB Fellow.
A new strategy enables precise fabrication of nanoporous carbon structures
Nanoporous carbon materials have attracted significant interest for applications in lightweight structural materials, microdevices, and bio-integrated systems due to their low density, chemical stability, electrical conductivity, and tunable mechanical properties. However, existing fabrication approaches often struggle to simultaneously achieve precise patterning, controllable porosity, and desirable mechanical performance. A research team led by Professor Min Qiu at Westlake University has developed a new fabrication strategy, termed Mix-ice lithography (Mix-IL), that enables direct construction of nanoporous carbon structures with tunable pore architectures and complex geometries. The study has been published in Science Bulletin.
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
/PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a...
Traditional Inuit Diet: Foods, Nutrition, and Health Effects
Traditional Inuit diets combine nutrient-dense marine and terrestrial country foods that remain important sources of protein, vitamin D, vitamin B12, iron, and other essential nutrients. The transition toward market foods is occurring alongside changes in cardiometabolic health, micronutrient intake, and gut microbiome patterns, while food insecurity, socioeconomic conditions, physical activity, colonial processes, and environmental change complicate the relationship between diet and health.
50 countries and counting, she now finds value in slow travel
Social media made travel feel like a competition. Seeing country counts in people's bios made Macie Strum start keeping score.
Study Findings Conflict with Body of Science Linking Pesticides to Attention Deficits and Autism - Beyond Pesticides Daily News Blog
A recent study finds no connection between levels of urinary biomarkers of organophosphates and autism-related traits, conflicting with a wide body of research.
Reaction: “Fabio looked dangerous from his first touch”
(in the mixed zone): “He had circulation problems (regarding the substitution of Konstantinos Karetsas, ed.). There had been no sign of it. He went to the hospital for further examinations. It would...
Have we found alien life? Hundreds of scientists weigh in
Two major alien-life announcements in 2025 generated enormous excitement, but most astrobiologists remained unconvinced. Only 6.6% of surveyed experts thought possible biological molecules on K2-18b probably represented extraterrestrial life, while 15.1% said the same about intriguing mineral patterns in a Martian rock.
Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize
Cleveland Clinic, RIKEN and IBM has been named as a finalist for the 2026 ACM Gordon Bell Prize for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching a scale of 12,635 atoms.
Why General AI Coding Assistants Fall Short in Science
Generic AI coding assistants struggle with scientific workflows. Rolv v3 adds reproducibility, biomedical intelligence, HPC execution, and visual DAGs.
Unlocking Forest Diversity from Above: Fieldwork at Smithsonian’s BiodiversiTREE
Laying groundwork for using airborne remote sensing to better understand the characteristics of forest species diversity.
U.S. Department of Health announces key leadership changes at FDA
The U.S. Department of Health and Human Services on Tuesday named four senior leaders at the U.S. Food and Drug Administration, including the heads of its drug center and vaccines and biologics unit.
U.S. Department of Health Announces Key Leadership Changes at FDA
Sept 8 (Reuters) - The U.S. Department of Health and Human Services on Tuesday named four senior leaders at the U.S. Food and Drug Administration, including the heads of its drug center and vaccines and biologics unit. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim ...
Drug developed for lung disease may slow biological aging in surprising ‘bonus’
Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, made patients appear three to four years biologically younger in a clinical trial.
Microbiome transplants may curb food allergies
Gut microbe transplants treated some peanut allergies in an early-stage clinical trial.
Next Apple TV's Chip Revealed in Latest Leak
The next Apple TV 4K will be equipped with an A19 or A19 Pro chip, according to evidence in Apple's code uncovered by MacRumors contributor Aaron Perris. In particular, the device's model identifier points towards the A19 generation of chips. Accordingly, the next Apple TV would have 8GB or 12GB of RAM, up from 4GB in the current 2022 model with the A15 Bionic chip.
Growth in every postcode: good politics, dubious economics
The UK government would be better off backing clusters and widening access to opportunity
Youth with CF on approved treatment still face mental health issues
Youth with cystic fibrosis continue to experience mental and behavioral health concerns despite treatment with Trikafta, according to a study.
Neither political donations nor special interest groups should dictate policy
Letters: Readers respond to George Monbiot’s article on Andy Burnham and political donations
Are rich people really worse behaved? Here’s the science
Who’s more likely to steal sweets from a child? According to science, it’s the rich. A study seemingly confirming our suspicions about the moral behaviour of the wealthy was one of the winners of the 2026 Ig Nobel prizes, which honour research that makes you laugh and then think. Science editor Ian Sample tells Madeleine Finlay what the researchers think could be behind the phenomenon, and they explore some of the other awards, including one for a surprising quality we look for in our friends and another for a biomechanical definition of kissing
How the lowly egg could help protect future spacecraft
Bioinspired designs could be sturdy astronaut allies.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
SC's Emerging Biotech Industry Receives National Recognition
Genetic Engineering & Biotechnology News (GEN) recently named the Palmetto State among its “Regional and State Clusters to Watch” in its first-ever Next 10 U.S. Biopharma Clusters report, highlighting emerging life sciences ecosystems beyond...
The New York Times
Seven of Ukraine’s top 10 military contractors won new business despite open criminal investigations for fraud, failures to deliver on earlier deals or the arrest of chief executives for corruption,...
Ozempic and Wegovy may have an unexpected mental health benefit
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.
Daniel Farke provides fitness update ahead of Chelsea clash
After a quick turnaround following the weekend’s Premier League draw at Brighton & Hove Albion, attentions now turn to the trip to Chelsea for Wednesday’s EFL Cup Round Three tie for Daniel Farke�...
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Scientists found two bat species never known to science in Cameroon’s rainforest after studying bats that looked almost identical
Deep inside the rainforests of southeastern Cameroon, scientists have identified two bat species that had never been formally recognised by science. The discoveries came from surveys in and around Lobéké National Park and the Dja Biosphere Reserve, where researchers examined a small collection of forest bats belonging to the genus Glauconycteris.
Korea freezes 2027 health insurance premium at 7.19%
The government has decided to freeze the national health insurance premium rate at 7.19 percent in 2027, citing stable finances and expected support from the government and premium revenue.The Ministry of Health and Welfare said that the Health Insurance Policy Deliberation Committee approved the 20
How hurricanes triggered lizards' rapid evolution
Hurricane season is upon us and it turns out that these powerful storms can quickly affect the biology of animals. After hurricanes Irma and Maria hit the islands that make up Turks and Caicos about a decade ago, the silver key anole adapted. They now have a shorter fourth toe on their hind legs! That could help them cling to objects better. But how do you know unless you put lizards in front of a fan and record how long they can hold on?This study is out now in the journal Current Biology.Interested in more science in the news? Email us your question at shortwave@npr.org.Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
Ribbon Bio Appoints Jay Therrien as Chief Business Officer
Cell-free DNA assembly pioneer, Ribbon Bio, has today announced the appointment of Jay Therrien as Chief Business Officer. Therrien joins Ribbon's executive leadership team where he will lead the company's commercial strategy and growth initiatives.
CSU biology professor delivers talk on extremophilic microorganisms, research advancements
Thomas Santangelo began the department of biology’s fall semester seminar series at Colorado State University strong, presenting the progressive research behind microorganisms in extreme environments and how those observations can inform future research about biological resilience and adaptation. Santangelo, a professor of biochemistry and molecular biology at CSU, was the main speaker of the “Surprises...
GenSight Biologics Provides September 2026 Business Updates
PARIS, September 08, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided business updates covering the summer of 2026 and confirmed the publication date for the Company’s financial statement covering the first half of 2026.
4 CDMOs to consider when outsourcing manufacturing
Contract development and manufacturing organizations looking to do business with biopharmas include Lonza, which has more than 30 sites, and Samsung Biologics, which recently announced a planned acquisition of another CDMO.
Perilla frutescens Benefits: Effects on Allergy, Inflammation, Immunity, and Gut Health
Perilla frutescens contains phenolic acids, flavonoids, and other bioactive compounds that show anti-allergic, immunomodulatory, anti-inflammatory, and gut-protective effects across laboratory and animal studies. Limited human evidence, including a small randomized trial of rosmarinic-acid-enriched Perilla extract for seasonal allergic rhinoconjunctivitis, is promising, but larger standardized clinical trials are needed.
Fired DeSantis campaign staffer Nate Hochman lands senior State Department role under Marco Rubio
Former DeSantis staffer rebounds into senior Rubio State Department role.
Why Scientists Asked More Than 1,000 People to Bury Their Underwear to Study Soil Biodiversity Across Switzerland
More than 1,000 volunteers buried cotton underwear across Switzerland to help scientists study soil biodiversity and biological activity.
Democrats Condemn NIH-DOD Research Agreement
The Defense Department could tap up to $2 billion in federal research dollars designated for biomedical research, under an agreement signed with the National Institutes of Health.
Small bowel microbiome offers clues to women's health
A new study by investigators at Cedars-Sinai Health Sciences University has identified differences in the makeup and organization of the small bowel microbiome between women and men. The findings, published ...
Scientists covered 200 square metres of a Swiss glacier with sheep’s wool; early tests found it protected the ice about as well as plastic sheets, but only 0.02% of Swiss glacier ice is covered
A natural wool covering placed over 200 square metres of high-altitude Alpine ice has proved as effective at slowing summer melting as conventional synthetic tarpaulins, offering a possible biodegradable alternative to plastic sheets. Initial results from the "Keep It Wool" trial on the Tsanfleuron Glacier in western Switzerland show that prototype wool blankets protected snow and ice from heat about as well as plastic geotextiles.
Scientists Discover Soil Bacteria Enzyme that Breaks Down Both Plastic and Antibiotics
Biologists studying how bacteria break down a new generation of plant-based bioplastics -- long-chain aliphatic polyesters -- have discovered an enzyme that can dismantle both plastic and antibiotics.
Minecraft's next update is called Wilderness Bound
After teasing a new biome and treasure-filled camps during Minecraft Live 2026, this upcoming update finally has a name: Wilderness Bound.
Serie A: Cagliari vs. Lecce
Fabio Pisacane and Eusebio Di Francesco have confirmed their selections as Cagliari host Lecce at the Unipol Domus in the penultimate match in the third round of 2026-27 Serie A fixtures.Cagliari have...
Robert Pattinson responds to Chris Hansen’s ‘Primetime’ casting criticism
Robert Pattinson addresses Chris Hansen’s ‘Primetime’ casting criticism after former ‘To Catch a Predator’ host named the actor he would have chosen to portray him in a biopic.
The bioinformatics escape room where guests become genetic detectives
A Northeastern professor created a bioinformatics escape room to introduce newcomers to a growing career field.
The best new popular science books of September 2026 include new titles by Carlo Rovelli and Xand van Tulleken
Dive into new titles from major names including Carlo Rovelli, Maggie Aderin, Xand van Tulleken and Jim Al-Khalili, as well as a new biography of Stephen Hawking
Protein Pop launches 15 g protein and prebiotic soda for gut health
Rise Wellness has expanded its Protein Pop range with a zero-sugar sparkling beverage combining whey protein, collagen and five grams of fibre
A Shared Biology Underlies 5 Major Fatigue-Causing Illnesses, Scientists Suggest
“A biological unifying theory of fatigue.”
Prof Elizabeth Streicher unravels the science behind drug-resistant TB
Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics delivered her inaugural lecture on Tuesday 1 September 2026. Her research focuses on the transmission and spread of Tuberculosis (TB). Knowing where TB transmission is happening can help to stop it from spreading. Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics in the Faculty of Medicine and Health Sciences delivered her inaugural lecture on Tuesday 1 September 2026. The title of her lecture was Decoding tuberculosis: the evolution of technology, epidemiology and the Mycobacterium tuberculosis genome. Streicher explained to Corporate Communication and Marketing how molecular epidemiology (using genetic information to track how and why diseases spread through populations) has improved our understanding of where drug-resistant TB comes from, how it spreads and how drug resistance evolves within and between populations. Tell us more about your research and why you became interested in this specific field. Overall, our research group studies the genome (complete set of DNA instructions found in a cell) of Mycobacterium tuberculosis, the bacteria that cause tuberculosis (TB) disease. Various regions of the genome are interrogated to study different aspects of the disease. My main focus has been on the epidemiology of tuberculosis – how the bacteria’s genome changes over time and what this tells us about the transmission and spread of the disease. How would you describe the relevance of your work? If we understand how the bacteria that cause TB change and spread, it can assist in combating TB globally. How has molecular epidemiology helped improve our understanding of drug-resistant TB? Molecular epidemiology was very important in drug-resistant TB as it was originally believed that bacteria that become resistant to antibiotics would be less fit and not be able to transmit. But it was shown that they can transmit, and therefore have to be monitored to identify hotspots of transmission and outbreaks, etc. Can you tell us briefly about the spoligotyping technique and its advantages for studying drug-resistant TB? Spoligotyping (a molecular technique used to identify and track specific strains of TB bacteria) does not detect drug resistance, but since the technique is relatively quick to do, it can be very useful in real-time situations, e.g. to monitor outbreaks of drug resistance. Why are interrupting transmission chains and identifying genomic hotspots important for controlling the spread of TB? Knowing where TB transmission is happening can assist in allocating resources to those areas to stop future transmission and spread of TB. Higher education can be challenging. What keeps you motivated when things get tough? Students – how they are so passionate and dedicated to learning and contributing to research and society as a whole. What aspects of your work do you enjoy the most? Again, the students and colleagues! But also the fact that it is continuously changing and thereby we are learning and expanding our knowledge. In the end, I know that we contribute to a better society in our small way. Tell us something exciting about yourself that people would not expect. Even though I love hiking (day and multi-day hikes) and being outside, I really do not like camping! How do you spend your free time? I love hiking (wellbeing in nature) and like to watch most sports. ©Higher Education Media Services. Subscribe
Early Data Indicates an A.I.-Generated Drug Could Slow Aging
Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.
Capello: Why Roma can challenge Inter for Serie A title
Fabio Capello feels Roma can pose a strong challenge to Inter for the 2026-27 Serie A title: ‘When you have quality players in the final third, anything can happen.’Inter and Roma are the only two...
Capello lauds Roma: “They’re the true anti-Inter.”
Fabio Capello believes in Gian Piero Gasperini’s Roma. The former Giallorossi coach, interviewed by Gasport, identified the Roman team as Inter’s main rival in the Scudetto race, focusing on the s...
Slegers praises debutants in victory at Brighton & Hove Albion
Arsenal head coach Renée Slegers praised her summer signings after The Gunners claimed a 1-0 victory over Brighton & Hove Albion at Broadfield Stadium on Sunday afternoon.A 10th-minute goal for debut...
SEERS’ AI-powered wearable ECG monitor wins Health Canada approval
SEERS, a wearable AI diagnostic monitoring company, said Monday that its AI-powered wearable electrocardiogram analysis solution mobiCARE has received a Class II Medical Device Licence (MDL) from Health Canada.Health Canada granted the licence last Thursday (local time), following an application sub
Cuba: US Embassy issues health alert due to GI pathogens like norovirus, Shigella
The US Embassy in Havana issued a health alert last week after seeing a significant increase in diarrheal illness across Cuba, associated with the continuing degradation of the water and energy infrastructure. This degradation affects water supply, and food storage and temperature control. Recent cases have included E. coli, norovirus, Shigella, and other gastrointestinal pathogens. This comes after a health alert dated August 28 which noted that Cuba’s water delivery infrastructure is increasingly unstable. The Embassy is aware of reports of residential neighborhoods that have gone for long periods without receiving water from municipal or public sources. Dengue cases surge in the Tampa Bay area Prolonged and worsening water issues and power outages caused by the regime’s mismanagement of public infrastructure impact the entire island. Water often only flows to residences when city power is on for a sufficient amount of time. Media reports indicate wells are running dry across the country due to drought, aggravating the ability to supplement water delivery. The lack of water, coupled with power shortages that have disrupted cold chain networks, can present significant health and safety challenges. We remind U.S. citizens to be aware of the risks when traveling to Cuba and take precautions. Embassy officials offer the following precautions to prevent illnesses: Avoiding Foodborne Illness: Be cautious of meat, poultry, seafood, eggs, dairy, and other perishable foods that may have been inadequately stored. Avoid foods that appear to have been sitting at room temperature for extended periods. Avoid raw or improperly washed vegetables. Be cautious of food cooked and then cooled, stored, or reheated, as improper temperature control can allow pathogens or toxins to develop. Wash hands thoroughly with soap and water before eating and after using the restroom. Hand sanitizer may be less effective against certain gastrointestinal pathogens, including norovirus. Outbreak News Today is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe Water Safety: Use only water known to be safe for drinking, brushing teeth, making ice, and cooking. Use bottled or appropriately treated water; check that bottle seals are intact before opening. Avoid ice unless the water source is known to be safe. Do not use untreated tap water to prepare beverages or food. Be aware that contamination can occur when food, utensils, and surfaces are washed with contaminated water. If You Become Ill: Stay hydrated, especially with frequent diarrhea or vomiting. Most illnesses are self-limited and improve within several days. Seek medical attention for persistent or severe diarrhea, bloody stools, high fever, significant abdominal pain, repeated vomiting, signs of dehydration, or symptoms not improving. Common medications (e.g., acetaminophen, ibuprofen, antibiotics) are frequently unavailable in Cuba; consider bringing your own supply. If you like the reporting on Outbreak News Today, please consider a paid subscription for $5/month or $30 a year. Help support the cause of this niche journalism. It is appreciated.
The science behind the beauty business
Some of Europe’s industrial champions may be in retreat, but its cosmetics sector remains a global leader, buoyed by healthy demand, recognised brands and a reputation for innovation."The fact is, the science in cosmetics is better here in Europe than anywhere else in the world,” says Pierre Morvan, CEO of Technature, a private label cosmetics manufacturer located near Brest in France’s northwestern Brittany region. “You have to have good science in order to make the difference, and that is why we invest so much in research and innovation.”Across Europe, the beauty and skincare products sector supports an estimated 3.6 million jobs, including 265,000 employed directly in the industry, according to the Cosmetics Europe trade group.. Cosmetics production contributes an estimated €11 billion to the EU economy, and generated €30 billion in export revenue last year, a €400 million rise from 2024.Technature itself has a global footprint, supplying products for 1,500 brands in 65 countries. Its range of skin gels, facial masks, nail treatments and other products include natural ingredients and extracts derived from plants, such as seaweed, that are developed and refined through science-based analysis and testing.While industry projections point to sustained growth for the foreseeable future, driven by emerging economies and wider availability of exclusive brands that were once chiefly sold by high street retailers, the sector is not immune to the impact of geopolitics and trade wars. The Trump Administration’s tariff threats have dented cosmetics exports to the EU industry's largest overseas market. After the European Parliament approved the EU-US Turnberry Agreement in June, setting a 15% levy on many EU goods, the French Federation of Beauty Companies warned that “exports are falling sharply” and urged the EU to negotiate an opt-out for cosmetics.Technature’s CEO flags South Korea as an emerging competitor, partly due to its assertive marketing efforts. “I would have to say I am a little bit scared,” Morvan says, regarding the growth potential of the South Korean cosmetics industry. “This is why science and innovation are so important if Europe is to remain the leader.”With a workforce of 200, including biologists, chemists and other scientists, around 15% of Technature’s staff work in three research and development (R&D) labs. A similar number work in four quality control and assurance facilities, where science plays a crucial in ensuring product safety in a sector that is subject to the European Cosmetics Regulation.Educational exchange between industry and academiaIn recognition of Technature’s research and innovation, Morvan was selected as one of Brest’s ambassadors to Science Comes to Town (SCTT), a European initiative to strengthen communications and understanding between science and society. Brest is one of three coastal cities in the EU-funded programme, alongside Split (in Croatia) and Kiel (in Germany). From 7-11 September, Brest will host the EU TalentOn contest featuring 100 early-career researchers from across Europe.Morvan appreciates the value of engagement with educational and scientific institutions as well as the home community. For instance, Technature collaborates closely with university partners to enhance its in-house R&D. In addition, it invites students to its labs and sends its own researchers to local institutions. "We absolutely want the students to know what the industry is all about,” Morvan says, noting that seeing science in action can help young people “understand that they can do something real with science, to create something with what they are learning.” He says another important benefit: encouraging new generations of young people to consider a career in cosmetics.Community involvement also raises awareness about Technature and the skincare industry as a whole. “The public gains recognition of the innovative company that we are, and this is important for getting new customers,” Morvan says. One of its recent innovations — tiny, colourful cosmetic pearls that release skin moisturisers on application — was showcased at this year’s VivaTech event in Paris.Morvan holds a master's degree from the Brest Business School and studied animal production and biology in Brest at the University of Western Brittany (UBO), an SCTT partner, and at the University of Tours. He got his start in business in 2002, initially working on using seaweed as a raw material in the food industry before transitioning to cosmetics. Morvan has always been interested in connecting science and business, reflecting one the goals of SCTT to enhance public-private collaboration.The invitation to participate in SCTT was unexpected. “It was a surprise to get a call from the city of Brest saying that they wanted me on this programme,” Morvan recalls, adding that officials were drawn by his company’s R&D. “It's not only theory and science fundamentals. Our science is something that is applicable to the global market — and important for the community.”Science|Business, which connects policymakers, academics and industry through its news reporting, analysis and events, is an SCTT partner.
Merrimack Anheuser-Busch Property purchased by United Therapeutics Corporation
Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack for $47 million, according to sources familiar with the matter. The transaction secures one of Southern New Hampshire’s largest industrial parcels, spanning nearly 300 acres off Daniel Webster Highway
In 2019, scientists shut off rain inside Arizona’s Biosphere 2 rainforest for 9.5 weeks; carbon storage fell about 70% before the forest recovered
Researchers turned off the water supply to the tropical rainforest inside Arizona's Biosphere 2 in 2019, and watched the ecosystem respond to an artificial drought. The experiment lasted four months in total, which included the recovery period, while the forest itself went without rain for about 9.5 weeks.
In 1996, Columbia scientists shifted Biosphere 2’s 2.6-million-gallon Arizona ocean between ice age, modern and future CO₂ every 3 months; future chemistry cut coral calcification by about 40%
For years, scientists argued about whether it would be safe for the ocean to absorb the carbon dioxide that people release into the atmosphere. When Biosphere 2 began, it was a widely reported experiment in which people lived in confinement to test whether a closed biosphere could support them.
KAIST identifies cause of artifacts in battery nanoscale analysis, paving the way for more reliable measurements
- A research team led by Professors Seungbum Hong and Jong Min Yuk from the Department of Materials Science and Engineering and Professor Nam-Soon Choi from the Department of Chemical and Biomolecular Engineering has identified the cause of a measurement artifact in nanoscale battery analysis that can make surface topography appear to represent ion movement. - The team has developed a method to reduce these artificial signals by smoothing rough battery-material surfaces, potentially improving the accuracy of analyses for next-generation batteries, including conventional lithium-ion batteries and emerging technologies such as sodium-ion and solid-state batteries.
8 Subtle Signs Your Gut Health Might Be Affecting Your Mood, Skin, or Energy
Gut health is linked to so many facets of overall health that you might not even realize which mental and physical signs actually link back to the state of your microbiome. Here are some common and surprising signs of poor gut health, and easy steps to improve your gut health naturally.
Businesses in Grimsby to campaign about derelict buildings
Traders on Cleethorpe Road in Grimsby are demanding action over The Albion and a building opposite.
Mastantuono taken out of Fiorentina’s game at half-time
Franco Mastantuono’s loan spell at Fiorentina is off to a troubling start. The Argentinian was subbed off at halftime in a 2-1 loss at home to Torino, as Fiorentina remain winless and pointless in Serie A. Mastantuono has been starting for his new team, but head coach Fabio Grosso will be forced to make some […]
"Old Person Smell" Is Real, And Science Will Dictate Whether It Happens To You
"That smell is an actual biological phenomenon."
Kenosha car show brings thousands to downtown businesses
Organizers said this year's Kenosha Classic Cruise-In saw record attendance and participants.
San Francisco’s California Academy of Sciences is celebrating the state’s biodiversity with film screenings, community science events, and a nature festival this September
The California Academy of Sciences in Golden Gate Park is hosting various events this September, including a free nature festival.
Gabriel Gudmundsson: I have been waiting for this
Starting for the first time this season in Leeds United’s draw with Brighton & Hove Albion was defender Gabriel Gudmundsson, who was pleased with a point on his return to the team.Jayden Bogle’s f...
Nottingham Forest 0-0 Tottenham: What De Zerbi said
Tottenham Hotspur failed to have a shot on target in a Premier League match for the first time since April 2022 against Brentford under Antonio Conte. Tottenham Hotspur have failed to score in three successive Premier League games for the first time since November 2021, while it is the first time a Roberto De Zerbi side has failed to do so in Europe's big five leagues since Brighton and Hove Albion in January 2024.
Grosso aware Fiorentina could fire him after three defeats
Fabio Grosso recognises he could already be sacked after Fiorentina lost all three Serie A games, falling 2-1 to Torino. ‘That decision is for those above me.’If there were any doubts, it is no un...
Italy’s far-right Vannacci lashes EU in business summit address
By Valentina Za, Elvira Pollina and Francesca Landini CERNOBBIO, Italy, Sept 5 (Reuters) - Italy's rising far-right politician Roberto Vannacci told a high profile business forum on Saturday that the European Union should halt political integration and...
Italy’s far-right Vannacci lashes EU in business summit address
By Valentina Za, Elvira Pollina and Francesca Landini CERNOBBIO, Italy, Sept 5 (Reuters) - Italy's rising far-right politician Roberto Vannacci told a high profile business forum on Saturday that the European Union should halt political integration and...
Could a whale really swallow a human? We asked a biologist.
The new thriller ‘Whalefall’ depicts a diver trapped inside of a sperm whale.
Weak hydrogen bonds dethrone copper as the most stable metal binder, opening a new path for metal selection
- KAIST researchers reversed a decades-old metal-complex stability trend by tuning weak hydrogen bonds around the complexes without altering the metals’ direct coordination environments - The discovery could provide new design strategies for selective metal separation and recognition, catalysis, and biomimetic systems
ADHD UK Cannot Hide the Flawed Science Behind the Diagnosis and Its Treatment
The extensive critique of the biomedical account of ADHD and its treatment with stimulant medication has persisted for decades.
Brighton & Hove Albion vs Leeds United: Match preview
Leeds United head to the South Coast on Saturday afternoon looking to maintain their unbeaten start to the 2026/27 Premier League season, but Daniel Farke’s side face one of their toughest tests yet against a Brighton & Hove Albion side who have already shown just how dangerous they can be in front of goal.
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]
15 discouraging hours with Onimusha: Way of the Sword, and 10 brilliant ones with He Who Watches
In the last few weeks, while playing some video games that I might review, I emailed two cries for help. I sent the first to a rep for Capcom, confessing that the company’s samurai game Onimusha Way of the Sword (out today for PC and console) was crushing me. “Feels like I’m playing ‘hard’ mode, not ‘normal,’” I wrote. “And I don’t want to have to knock it down to “story”. I’m exploring, trying to level my gear, but these two-phase boss fights with no mid-fight checkpoints are brutal.” I wagered I was only about halfway through the game, if that. I wasn’t sure I could keep up with the steepening difficulty curve. Was I missing something? Then, on Monday, I took some photos of some puzzles that were baffling me in the mind-bending He Who Watches (out now on PC), wrote out lengthy descriptions of how I’d been trying to solve them and asked Bobby Vanden, the game’s solo developer, for a nudge in the right direction. I told Vanden I’d spent hours on these puzzles. “I’m stuck in triplicate,” I told him. Could he tell me if the solutions I was attempting were even on the right track? I didn’t mention that the puzzles—coupled with major time pressures from other work—were stressing me out so much that playing the game was giving me headaches. This double dose of panic was unusual. I’m used to managing a workload full of reporting and reviewing, used to a crowded schedule and the need to stay calm amid the bustle. But I was stressed about these games. No one was forcing me to review them, nor even play them. I’d simply found them interesting enough to start, hoped they’d be interesting enough to write about and I’d sunk hours into them assuming I’d made the right call. Suddenly, however, I felt trapped. I was emailing for a way out. Above: This guy took me about an hour to beat. The feedback I got from Capcom confirmed my fears. They didn’t say it, but I will: Onimusha Way of the Sword is not for me. It’s a brutally hard game in need of a normal difficulty level. It’s a game that spikes so severely during its abundant boss fights—yet offers such flawed ways to improve when outside of them—that it feels like a bait-and-switch. In the new Onimusha, you play as famed samurai Musashi Miyamoto, aided by a magical soul-absorbing gauntlet that is possessed by a lady who offers advice. (Way of the Sword is a continuation of Capcom’s long-dormant Onimusha series, but that set-up had me wondering if the company was cribbing from their ill-fated Bionic Commando reboot; read about “wife-arm” when you get a chance). Way of the Sword is partially set in 17th century Kyoto, an explorable city where Miyamoto can fight demons, help civilians and eventually rescue ghostly dogs. The city evolves over time, with new mini adventures and obtainable loot on offer, all feeding into systems that promise to upgrade your gear and sword-fighting skills. Upgrades, however, are so incremental as to be imperceptible, causing the exploration of Kyoto to feel like inconsequential busywork. From that hub, players can go on linear missions into forests and old temples, where they will encounter many of the game’s tough bosses. Combat in Way of the Sword is akin to many modern melee games. Players are asked to mix attacks with dodges and parries. They’re encouraged to deplete an enemy’s stamina bar in order to do greater damage to its health bar. The old Onimusha games’ signature move was the issen, a counter-attack so sudden it’s all but pre-emptive. You strike just as they begin to strike toward you, beating them to the cut. By definition, the issen is a high risk move, leaving you wide open to pain. It feels risky in the game, especially against bosses, who can maul you in just a few blows. A game might train you to perform an issen well by offering a variety of lesser enemies who are not as tough as the boss but get close. Or it might offer a toehold against bosses by saving or checkpointing the player’s progress when a boss’ first health bar has been destroyed and before the second health bar appears. It might offer the less skilled player a chance to over-level their character, should the player simply commit to playing through its optional sidequests. Way of the Sword does none of this. Fighting its trivially easy grunt enemies and then its ferociously adept bosses is like playing a game of chess where I’ve got a rook, while the opposing side is all pawns and five queens. Bosses simply don’t checkpoint. You may be able to clear a boss’ first phase without taking much damage. Good for you. Do it again, every time you fail the second phase. As for the the central Kyoto hub, I kept pace with all of its added side activities and never felt like I was overpowered. Bosses could still easily buckle me. The new Onimusha, I concluded, is just too discouraging to keep playing. The advice I got from Capcom had been well-intentioned. They reminded me of the game’s various systems. They alerted me to an optional assist that flashes recommended button inputs (basically: counter this move; dodge that move). It was a little helpful. So was dropping down to “story mode,” which I tried last night. Story mode turns on those button prompts by default. It makes countering and dodging way too easy, nearly automatic. I don’t consider myself a master of action games like these, but I’ve cleared the likes of God of War, Stellar Blade, Star Wars Jedi and others of sub-Sekiro difficulty and had a fun time doing so. Not here. Not yet. Unless they patch Onimusha: Way of the Sword and add a middle difficulty or just checkpoint the damn bosses when they’re between health bars, my streak of loving Capcom games released in 2026 will likely end at two. It’s a shame, because I was having a good time finding those ghostly dogs. And then there’s He Who Watches, a phenomenal first person puzzle game with Portal vibes, except instead of a portal gun you’ve got a magical bow that shoots one arrow that can activate switches or be used to drag blocks. The twist is an actual twist: you can also walk on walls and the ceiling, reorienting gravity as you do, thereby placing blocks onto those other surfaces. Walking on walls and ceilings to solve problems is really the best thing. Would that I could in reality. He Who Watches consists of locked-room challenges, each brief enough to only require about a minute to actually solving, though it will take five, 10, eventually 30 minutes to figure out said solutions. They are not obvious! It’s a game of layered mechanics and shocking solutions. For example, see if you can follow this: You can drag a block to a wall. Then you can walk on the wall, which now feels like the floor, and drag that block across the wall. Later, back on the floor, you might realize you can look up. The block is still on the wall, stuck to it. You can shoot your magic arrow to its underside. Doing so creates a tether, so that you can yank the block off the wall and carry it, as if it were a balloon, into the spot where you need it to be to solve the puzzle. Here, watch Vanden explain some of the game’s basics in this launch trailer: As with any great puzzle game, the solutions to He Who Watches’ puzzles elicit relief and amazement. Oh my god, that worked! I didn’t even think that could be possible! Learning to solve the game’s puzzles feels like learning magic. But, oh, does the game get hard. Its Steam reviews, mostly glowing, are full of players remarking how quickly He Who Watches made them sweat. Wrote one: “loving this one already although my brain is hurting!” Wrote another: “As you get further in the game it feels like you need an IQ level of at least 120+.” Vanden has shown some mercy. Each locked room puzzle includes an optional junior version of the puzzle, meant to teach you. Difficulty nevertheless ramps severely. By the time I was emailing Vanden for help, I was struggling to even clear one of the hint puzzles. When I messaged him, my stress was exacerbated by strange things I’d found in the game’s various hubs: suspicious passageways, odd blocks and some intriguing locked doors. These were hints of secrets, I realized, yet I sensed I needed to play further into the game to understand them. I was stuck, but I wanted to see the rest. Vanden offered to give me the exact solutions, to solve those three puzzles for me, but first he gave four nudges. Three were for the specific puzzles, but his best hint was for all and ultimately proved to be a terrific life lesson: go back a bit, he suggested. Do the puzzles right before those. They were teaching you something. Focus on what their lesson was. Don’t rush, in other words. Recognize what you’ve accomplished. Build off of that. I did so. I absorbed the lessons. I saw those three tough puzzles in a new light. I solved one the night after he wrote back, another the morning after. I left a third for another time. I didn’t need it and I wanted to plunge deeper into the game, closer to the moment when I was sure I could start unlocking those secret doors. My head stopped hurting, too. He Who Watches feels special. It’s got more challenges, and I’m undeterred. It’s also nice that its puzzles don’t have a surprise second health bar. Game File is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe Item 2: In brief… 🎮 Ilari Kuittinen, co-founder of Helsinki-based Housemarque (Super Stardust HD, Resogun, Returnal) has stepped down from his studio, after a 31-year run, saying he’s “ taking a rare and well-deserved breather.” Sony purchased Housemarque in 2021, and the studio released its newest game, Saros, earlier this year. Trend-watch: Sony-owned Insomniac saw its founder Ted Price retire in early 2025, after a 30-year run. Sony-owned Sucker Punch saw its co-founder Brian Fleming step down in late 2025, after a 28-year run. 👀 Savvy Games Group chief Brian Ward is stepping down from the Saudi-government-backed games conglomerate, Bloomberg reports. No word on a long-term successor yet, nor if this augurs any closer integration between Savvy and Electronic Arts. EA was purchased by a consortium led by Saudi’s sovereign wealth fund, in early August. 💿 Square Enix has denied a Japanese media report that the company was planning to go private. In very different Square Enix news, the company revealed that the physical version of Final Fantasy VII: Revelation, the April 2027 finale of its radical remakes of FFVII, will include just one disc in its case, requiring a download for the rest. The first two FFVII remakes in the trilogy shipped on two discs apiece. While Square hasn’t commented on the reason why, a feature here in Game File last month broke down the processes and costs for physical games. The expense of a second disc comes out of the game publisher’s cut of each copy. Square could be saving in excess of a dollar a copy with this move. 🟥 Grand Theft Auto IV’s 26-minute ’‘extended look” gameplay showcase that premiered on Netflix last week—and was exclusive to the platform for six hours—drew 31.1 million views in its first four days, the streamer announced. (Netflix calculates views as total viewed hours divided by runtime; excludes replays). Compared to YouTube: The version that later premiered on Rockstar Games’ YouTube channel is sitting at 22.6 million views after seven days (YouTube’s more liberal counting system tallies anyone who viewed even just the first few second.) Compared to other Netflix mega-events: Last year, Stranger Things season 5’s first four episodes, which debuted together, drew a record 59.6 million views in their first few days on Netflix. For more of a live event type of comparison, in 2024, the Jake Paul vs. Mike Tyson boxing match drew 65 million concurrent streams as it happened; Netflix didn’t release live numbers for the GTA premiere. ☁️ Microsoft is changing the way it charges for cloud gaming, from an all-you-can-play offer for Xbox Game Pass subscribers, to caps for the subscription’s tiers (15 hours per month at the Ultimate tier), with the option to buy more hours in bulk beyond that. The company also said it will sell batches of cloud gaming time to non-Game Pass subscribers, details TBA. Microsoft does not release figures for cloud game usage, but said its changes would impact 4% of Game Pass subscribers. That implies a small portion of its subscribers exceed the 15-hour monthly mark. Cloud gaming offers the promise of playing games without the need for console or PC hardware, as the graphics, sound and controls are all transmitted via a streaming connection. Microsoft notes that its cloud gaming service can be used for a range of things, including Xbox One players using it to play newer-gen Xbox Series games via streaming; and people playing games via streaming, sans any console, “in markets where consoles are less available or affordable.” (That latter use case could even be relevant in Xbox’s home market soon, as console prices keep rising.) Take Two Interactive chairman Strauss Zelnick recently told investors he expects game-streaming tech, which has been only lightly adopted by gamers for over a decade, to be widely used within three years. 🇺🇸 The Trump administration has published multiple agenda-driven web video games to the White House’s website. One called Build The Wall partially clones Tetris as it asks players to build a wall to stop a “zombie border siege.” While actual Tetris involves clearing lines and basically not building a wall, the Trump-backed game omits the line-clearing aspect (and omits the fun as well). On Instagram, Tetris’ official license holders reacted by stating: “At Tetris we believe in the power of connection and bringing people together, not dividing them. To our fans everywhere: we love you, we see you, and we’re grateful to have you in our community. P.S. The Tetris Company was not involved in the creation of ‘Build the Wall.’ P.P.S.: We take copyright infringement very seriously.” Item 3: The week ahead: Tuesday, September 8 Game releases: Mewgenics (consoles; already out on PC) is an engrossing tactical combat game (with cats). It is getting its console port right after the release of a Star Wars tactics game and ahead of the late September launch of a Fire Emblem–a bumper crop for the genre. Wanderburg (PC) is an auto-shooting game like Vampire Survivors, but you’re a castle on wheels Event: Nintendo airs a 30-minute Nintendo Direct (10am ET) focused on The Legend of Zelda’s 40th Anniversary. A full unveiling of the upcoming remake of The Legend of Zelda Ocarina of Time is expected. Will they also show footage from next year’s live action movie? Tease the next big 3D Zelda? Add Link to Mario Kart World? Shadow-drop a new Tingle game? Wednesday, September 9 Event: Nintendo again! On this day, they’re planning to air a 45-minute Nintendo Direct (10am ET) focused on games heading to Switch 2 this winter. Followed by about an hour of gameplay demoed by the company’s Treehouse team. The September Nintendo Directs are always some of the year’s biggest. The 2025 edition included announcements of several major 2026 Switch/Switch 2 games: Pokémon Pokopia, Mario Tennis Fever, Yoshi and the Mysterious Book, Fire Emblem Fortune’s Weave. Plus the return of the Virtual Boy. Friday, September 11 Game release: EA Sports NHL 27 (PlayStation, Xbox) is a hockey game. There are so few that an indie studio that had been making wacky sci-fi first-person shooters just announced that, hey, we’re going to fill a void and make a hockey game for PC.
Spot, snap and upload: Why California scientists want your nature photos
Use the iNaturalist app to track local species and help scientists protect California's unique natural heritage this Biodiversity week.
Pentagon agreement with NIH on biodefense draws alarm from Democrats
The deal is being criticized by Democrats who warn it could allow the Defense Department to go around Congress and gain access to billions of dollars meant for infectious disease research.
Scientists capture how bacteria build their protective antibiotic-resistant barriers
Gram-negative bacteria are responsible for causing several infections that are hard to treat, owing to their high resistance to antibiotics.
Pentagon Agreement With N.I.H. on Biodefense Draws Alarm From Democrats
Under a new partnership, the Defense Department would play a larger role in biodefense and pandemic preparedness. Democrats warned it could allow a Pentagon cash grab.
Baggies transfer window 'laser-focused'
Fan writer Chris Hall reflects on West Bromwich Albion's summer transfer window.
10 life sciences startups selected for accelerator program
Seven of the 10 companies participating in the fall cohorts of MassBio and SCbio’s Drive program are based in the United States, including four in Massachusetts.
Jaka Bijol: We have to be at our best
Ahead of Leeds United’s trip to the south coast to face Brighton & Hove Albion on Saturday afternoon, centre-half Jaka Bijol is expecting another tough test from our third Premier League fixture of ...
Pick of the stats: West Bromwich Albion v Watford
Here are the key stats for West Bromwich Albion v Watford.
Research into muscular degeneration wins top prize at Birla Carbon Symposium
Kennesaw State University biology student Pedro Santos’ research project on muscular degeneration in fruit flies won the top prize at the 2026 Birla Carbon Scholars Symposium.
Information for supporters travelling to the Amex Stadium
Leeds United travel to the Amex Stadium to face Brighton & Hove Albion in the Premier League on Saturday and we would like to thank every fan that will be making the journey to support the team.Ahead ...